Pathological Complete Response to Neoadjuvant Trastuzumab Is Dependent on HER2/CEP17 Ratio in HER2-Amplified Early Breast Cancer
暂无分享，去创建一个
M. Gnant | Z. Bago-Horvath | R. Exner | F. Fitzal | M. Seifert | C. Singer | A. Reiner | M. Filipits | G. Steger | F. Moinfar | M. Balic | E. Petru | R. Bartsch | Y. Tan | C. Gruber | M. Rudas | D. Egle | D. Fuchs | Farid | K. Tendl | Moinfar | M. Balić